Revenue from operations rose 13% to ₹873.25 crore from ₹773 crore, while earnings before interest, taxes, depreciation and amortisation (EBITDA) increased to ₹296 crore from ₹278 crore. However, the EBITDA margin contracted to 34% from 36% in the corresponding quarter last year.
The pharmaceutical company’s total expenses rose 13% on year to ₹695.75 crore from ₹615.48 crore. Profit before tax stood at ₹179.49 crore, up from ₹161.10 crore in the year-ago period.
Sequential performance
On a sequential basis, PAT attributable to owners declined 49.4% from ₹281.61 crore reported in the March quarter. Revenue from operations, however, increased 15.4% from ₹756.56 crore.
Total expenses rose 16.3% quarter-on-quarter from ₹598.18 crore.
Also read: Asian Paints Q1 Results: Stock jumps 5% after strong earnings beat, volume growth of 9%
Recent acquisitions and deals
Eris Lifesciences has been on an active dealmaking run over the past year as it deepens its play in injectables and speciality formulations. In November 2025, the company’s board approved buying out the remaining 30% stake in its subsidiary Swiss Parenterals for a total cash consideration of ₹423.3 crore, structured entirely as a share swap rather than a cash payout.
In February 2026, Eris also entered a partnership with Natco Pharma to jointly commercialise Semaglutide in India, a move aimed at strengthening its foothold in the fast-growing diabetes and metabolic-care space. The tie-up builds on Eris’s existing GLP-1 push through its own semaglutide brand, Sundae, and signals a broader push to consolidate its position as a leading player in India’s diabesity therapy segment.
Separately, in March 2026, Eris’s board approved a ₹50 crore acquisition of the branded probiotics business from Velbiom Probiotics. The acquired portfolio spans prebiotic and probiotic formulations targeting metabolic health, gut wellness and women’s health, giving Eris an entry point into the microbiome-therapy segment.
Eris Lifesciences shares gained 2.57% to close at ₹1426.5 on the National Stock Exchange on Wednesday.
